TickerFacts.

Celldex Therapeutics, Inc. (CLDX): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$1.34M
Year ended 2025-12-31
$12.04M2016-12-31: $5.19M2017-12-31: $12.04M2018-12-31: $8.84M2025-12-31: $1.34M$1.34M
2016-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$1.34Mn/a2026-02-25, From 2025-01-01
No annual figure between 2018-12-31 and 2025-12-31.
2018-12-31$8.84M-26.6%2021-03-29, From 2018-01-01
2017-12-31$12.04M+132.2%2020-03-26, From 2017-01-01
2016-12-31$5.19Mn/a2019-03-07, From 2016-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Celldex Therapeutics, Inc. (CLDX)2025-12-31$1.34Mn/a
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.30M+210.5%
Biomerica Inc (BMRA)2026-05-31$362.0K-27.3%
Anbio Biotechnology (NNNN)2025-12-31$7.54M+28.2%
Aspira Women's Health Inc. (AWHL)2025-12-31$5.92M+8.0%
Immucell Corp (ICCC)2025-12-31$11.45M+44.1%
Alpha Teknova, Inc. (TKNO)2025-12-31$13.44M+85.9%
Myriad Genetics Inc (MYGN)2025-12-31$576.60M-1.5%
Neogen Corp (NEOG)2026-05-31$408.50M-3.1%

Compare CLDX, IMDX, BMRA, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗